



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known 10/735,910

Application Number	Continuation of Appln. 10/270,313
--------------------	--

Filing Date	December 16, 2003
-------------	-------------------

First Named Inventor	Ru Chih C. HUANG et al.
----------------------	-------------------------

Group Art Unit	1614
----------------	------

Examiner Name	Mr. James H. Reamer LESUE ROYDS
---------------	--

Attorney Docket Number	2240-199065
------------------------	-------------

U.S. PATENT DOCUMENT						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	6,365,787		Huang et al.	04/2002	
	2	5,663,209		Huang et al.	09/1997	
	3	6,291,524		Huang et al.	09/2001	
	4	6,214,874		Huang et al.	04/2001	
	5	4,774,229		Jordan	09/1988	
	6	5,276,060		Neiss et al.	01/1994	
	7	6,071,949		Mulshine et al.	06/2000	
	8	4,425,327		Moller et al.	01/1984	
	9	4,880,637		Neiss et al.	11/1989	
	10	5,008,294		Neiss et al.	04/1991	
	11	5,559,149		Clum et al.	09/1996	
	12	5,827,898		Khandwala et al.	10/1998	
	13	5,837,252		Sinnott et al.	11/1998	
	14	5,965,616		Wang et al.	10/1999	
	15	6,165,788		Bennett et al.	12/2000	
	16	6,245,523		Altieri	01/2001	

[illegible]

**Examiner
Signature**

Date
Considered

12 AUGUST 2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	Of	2	Application Number	Complete If Known 10/735,910 Continuation of Appl. 10/270,313
				Filing Date	December 16, 2003
				First Named Inventor	Ru Chih C. HUANG et al.
				Group Art Unit	1614
				Examiner Name	Mr. James H. Reamer LESLIE ROYDS
				Attorney Docket Number	2240-199065

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examine r Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAR	17	Russell et al.; "Neoplasm inhibitors comprising metal salts and phenol derivatives"; CA: 111(3)17704R PATENT ABSTRACT	
LAR	18	Rao et al.; "Regioselective cleavage of the methylenedioxy group: conversion of (-)-austrobaillignan-5 to (-)-dihydroguaiaretic acid"; CA: 112(23)118499d JOURNAL ABSTRACT	
LAR	19	Giza et al., "A self-inducing runaway---replication plasmid expression system utilizing the ROP protein," Gene 78:73-84 (1989).	
already considered	20	Gnabre et al., "Isolation of anti HIV-1 lignans from Larrea tridentata counter-current chromatography," J. Chromatography A, 710: 353-364 (1995).	
LAR	21	C.W. Perry et al., "Synthesis of Lignans. I. Nordihydroguaiaretic Acid"; J. Org. Chem. 37(26): 4371-4376 (1972).	
LAR	22	Staal et al., "Antioxidants inhibit stimulation of HIV transcription," AIDS Research and Human Retroviruses, 9(4): 299-306 (1993).	
LAR	23	Weislow et al., "New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS---Antiviral activity," J. National Cancer Inst. 81(1): 577-586 (1989).	
LAR	24	Russell; "Compositions containing catecholic butanes and zinc for treating solid tumors"; CA: 110(12)101816r PATENT ABSTRACT	
	25	Chen et al., Antiviral Activities of Methylated Nordihydroguaiaretic Acids 2. Targeting Herpes Simplex Virus Replication by Mutation Insensitive Transcription Inhibitor Tetra-O-methyl-NDGA, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 16, pp.301-3007	
	26	Gnabre et al., Characterization of Anti-HIV Lignans from Larrea Tridentata, Tetrahedron 1995, Vol. 51, No. 45, pp. 12203-12210	
	27	Gnabre et al, Inhibition of Human Immunodeficiency Virus Type 1 Transcription and Replication by DNA Sequence-S-selective Plant Lignans, Proc. Natl. Acad. Sci., USA, 1995, Vol. 92, pp. 11239-11243	
	28	Gisvold et al., Lignans from Larrea Divaricata, Journal of Pharmaceutical Sciences, 1994, Vol. 83, No. 12, pp. 1905-1907	
	29	Hwu et al, Antiviral Activities of Methylated Nordihydroguaiaretic Acids. 1. Synthesis Structure Identification and Inhibition of Tat-Regulated HIV Transactivation J. Med. Chem. 1998, Vol. 41, No. 16, pp. 2994-3000	
	30	Huang et al., Regulation of HIV Promotor Activities in Human Embryonal Carcinoma Cells, NTERA-2, Gene Regulation and AIDS, 1989, pp. 147-160	
	31	Li et al, Transcriptional Analysis of Human Survivin Gene Expression, Biochem. J. (1999), 344 pp. 305-311.	
	32	Connor et al., Regulation of Apoptosis Cell Division by p34cdc2 Phosphorylation of Survivin, PNAS, Nov. 21, 2000, Vol. 27, No. 24, pp. 13101-13107	
	33	Li et al., The Cancer Antiapoptosis Mouse Survivin Gene: Characterization of Locus and Transcriptional Requirements of Basal and Cell Cycle-Dependent Expression, Cancer Research 59, July 1, 1999, pp. 3134-3151	

Examiner
Signature

Date
Considered

12 AUGUST 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.